Heart drug vyndaqel tracked in Real-World study
NCT ID NCT04108091
First seen May 19, 2026 · Last updated May 23, 2026 · Updated 1 time
Summary
This study looked at how safe and effective Vyndaqel is for people with a rare heart condition called transthyretin amyloid cardiomyopathy. Over 1,200 patients in Japan were observed during regular medical care. The main goal was to track side effects and see how many patients died from any cause or heart-related issues.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRANSTHYRETIN (TTR) AMYLOID CARDIOMYOPATHY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Pfizer
Tokyo, Japan
Conditions
Explore the condition pages connected to this study.